Penn Vet researchers have had success in treating various forms of blindness in dogs with gene therapy, setting the stage to
treat human blindness.
Not exact matches
ACT is now performing early - phase clinical trials testing the safety of implanting retinal cells derived from
human ES cells into the eye to
treat certain types of
blindness.
Retinal degenerative diseases, including age - related macular degeneration and Retinitis Pigmentosa (RP) are the predominant causes of
human blindness worldwide and are very difficult to
treat.
The findings suggest that cell - based therapies might be an effective way to
treat human corneal
blindness and vision impairment due to the scarring that occurs after infection, trauma and other common eye problems, said senior investigator James L. Funderburgh, Ph.D., associate professor, Department of Ophthalmology.
These findings suggest that RPE cells, derived from iPS cells, could be used to
treat blindness in
humans, such as
blindness caused by age - related macular degeneration, a leading cause of
blindness in the Western world.
Induced pluripotent stem cells have the potential to become any cell type; recently, this ability was used to generate retinal cells that were shown to rescue vision in blind mice, suggesting these cells could also be potentially used to
treat blindness in
humans.
Several groups have used retinal cells derived from
human embryonic stem cells to
treat different forms of
blindness.
When not
treated immediately, they can cause severe damage to a
human host and can even cause
blindness.
The dog has already played an important role in emerging therapies for inherited
blindness in
humans and similarities in disease phenotype and eye structure and function between dog and man, together with the increasingly sophisticated genetic tools that are available for the dog, mean that the dog is likely to play an ever increasing role in both our understanding of the normal functioning of the eye and in our ability to
treat inherited eye disorders.